Parenteral preparations are among the most technically demanding pharmaceutical dosage forms to manufacture.

Unlike tablets, capsules or syrups, parenteral products are introduced directly into the body through injection, infusion or implantation. They bypass many of the body’s natural protective barriers. Therefore, contamination, particulate matter, incorrect strength, bacterial endotoxins or loss of sterility may create serious risk for patients.

A parenteral manufacturing facility must have:

• Sterile manufacturing areas
• A strong pharmaceutical quality system
• Qualified technical personnel
• Controlled HVAC systems
• Pharmaceutical water systems
• Validated sterilisation processes
• Environmental monitoring
• Aseptic-process simulation
• Quality-control laboratories
• Container-closure integrity controls
• Detailed batch documentation

Quick Answer

Parenteral preparations include sterile injections, infusions, dry powders for injection, suspensions, emulsions and implantable preparations.

They may be classified as:

• Small-Volume Parenterals
• Large-Volume Parenterals
• Single-dose injections
• Multi-dose injections
• Liquid injections
• Dry-powder injections
• Lyophilised injections
• Terminally sterilised products
• Aseptically manufactured products

Whenever the formulation and container allow it, terminal sterilisation is generally preferred because it provides greater sterility assurance than relying only on aseptic processing.

Aseptic processing should be used when the product cannot withstand terminal sterilisation.

What Are Parenteral Preparations?

Parenteral preparations are sterile preparations intended for administration by:

• Intravenous injection
• Intramuscular injection
• Subcutaneous injection
• Intradermal injection
• Intra-articular injection
• Intrathecal injection
• Intraocular injection
• Intraperitoneal administration
• Intravenous infusion
• Implantation

They may be presented as:

• Solutions
• Suspensions
• Emulsions
• Dry sterile powders
• Lyophilised powders
• Concentrates for dilution
• Prefilled syringes
• Infusion solutions
• Implants

The route of administration, formulation, container and product stability determine the appropriate manufacturing process.

What Is an Injection?

An injection is a sterile parenteral preparation supplied in a container such as:

• Ampoule
• Vial
• Prefilled syringe
• Cartridge
• Infusion bottle
• Infusion bag

Some injections are ready to administer, while others must be diluted or reconstituted before use.

Examples include:

• Diclofenac injection
• Ceftriaxone dry-powder injection
• Insulin injection
• Iron-sucrose injection
• Dextrose infusion
• Sodium-chloride infusion

Small-Volume Parenterals

Small-Volume Parenterals, commonly called SVPs, are generally sterile parenteral preparations supplied in containers of 100 ml or less.

Examples include:

• 1 ml ampoules
• 2 ml ampoules
• 5 ml ampoules
• 10 ml vials
• 20 ml vials
• 50 ml infusion containers
• 100 ml infusion containers
• Prefilled syringes

SVPs may be:

• Single-dose
• Multi-dose
• Liquid
• Dry powder
• Lyophilised
• Solutions
• Suspensions
• Emulsions

Large-Volume Parenterals

Large-Volume Parenterals, commonly called LVPs, are sterile liquid preparations generally supplied in containers of more than 100 ml.

Examples include:

• 200 ml intravenous infusion
• 500 ml normal saline
• 500 ml dextrose infusion
• 500 ml Ringer’s lactate
• 1-litre irrigation or infusion solution

LVPs are usually single-dose preparations and normally do not contain antimicrobial preservatives unless specifically permitted and justified.

Common LVP containers include:

• Glass bottles
• Plastic bottles
• Flexible plastic bags
• Blow-Fill-Seal containers
• Form-Fill-Seal containers

Difference Between SVP and LVP

Point	Small-Volume Parenteral	Large-Volume Parenteral
Common volume	Up to 100 ml	More than 100 ml
Common containers	Ampoules, vials, syringes	Bottles and flexible bags
Dosage	Small injection volume	Large infusion volume
Single or multi-dose	May be either	Generally single-dose
Preservative	May be used in some multi-dose products	Normally avoided
Filling system	Ampoule/vial/syringe filling	Bottle, bag, BFS or FFS line
Common use	Injection or concentrate	Intravenous infusion or irrigation
Particulate control	Critical	Especially critical because of large volume

Liquid and Dry-Powder Parenterals

Liquid Parenteral Preparations

Liquid preparations may be:

• Aqueous solutions
• Non-aqueous solutions
• Suspensions
• Emulsions
• Concentrates for dilution
• Ready-to-infuse solutions

They may be terminally sterilised after filling or aseptically filled after sterilising filtration.

Dry-Powder Parenteral Preparations

Dry-powder injections are used when the active ingredient is unstable in solution.

Examples include:

• Antibiotic powders
• Certain biological products
• Lyophilised injections
• Hormonal products
• Enzyme preparations

The powder is reconstituted with an approved diluent before administration.

Single-Dose and Multi-Dose Parenterals

Single-Dose Container

A single-dose container is intended for use on one occasion for one patient.

Examples include:

• Sealed ampoule
• Single-dose vial
• Single-use prefilled syringe
• LVP infusion bottle

Multi-Dose Container

A multi-dose container permits withdrawal of more than one dose.

Such products may require an appropriate antimicrobial preservative, unless the formulation or route prohibits its use.

The manufacturer should establish:

• Preservative effectiveness
• In-use stability
• Maximum withdrawal period
• Closure integrity
• Suitable storage instructions

Main Sterility-Assurance Principle

Sterility cannot be assured only by testing a small number of finished containers.

It must be built into the complete manufacturing process through:

• Facility design
• Personnel practices
• Cleaning
• Disinfection
• Material controls
• Air filtration
• Water quality
• Equipment sterilisation
• Process validation
• Environmental monitoring
• Container-closure integrity
• Batch documentation

Terminal Sterilisation

In terminal sterilisation, the product is filled and sealed in its final container and then sterilised.

Examples include:

• Steam sterilisation in an autoclave
• Validated dry-heat treatment for suitable products
• Other validated methods where technically justified

Terminal sterilisation is preferred where the product and container can withstand the process.

Aseptic Processing

Aseptic processing is used when the product cannot tolerate terminal sterilisation.

In this process:

1. Product-contact equipment is sterilised.
2. Containers and closures are sterilised or depyrogenated.
3. Product is sterilised separately, commonly by filtration where suitable.
4. Product is filled under Grade A conditions.
5. Containers are closed while maintaining aseptic protection.

Aseptic processing requires stricter control of personnel, environment, interventions and equipment.

Regulatory Requirements in India

Manufacturing of sterile pharmaceutical products in India is governed by:

• Drugs and Cosmetics Act, 1940
• Drugs Rules, 1945
• Revised Schedule M
• Applicable pharmacopoeial standards
• Product-specific licences and permissions
• State Licensing Authority requirements
• Central Licensing Authority involvement for specified categories

CDSCO notified the revised Schedule M through G.S.R. 922(E) dated December 28, 2023. CDSCO subsequently issued notifications concerning its implementation timeline.

For Large-Volume Parenterals, CDSCO has also issued a public notice concerning manufacturing-licence applications in Forms 28D and 28DA through the ONDLS portal.

The exact licence route should be confirmed according to:

• Product category
• New-drug status
• Biological status
• LVP or SVP classification
• Loan-licence arrangement
• State and Central authority responsibilities

Contamination-Control Strategy

A modern sterile manufacturing facility should prepare a documented Contamination-Control Strategy.

The strategy should consider:

• Facility design
• Process flow
• Personnel movement
• Material movement
• Cleanroom classification
• HVAC
• Utilities
• Water systems
• Cleaning and disinfection
• Sterilisation
• Depyrogenation
• Aseptic interventions
• Environmental monitoring
• Personnel monitoring
• Raw-material bioburden
• Container-closure integrity
• Vendor qualification
• Maintenance
• Investigation of contamination
• Corrective and preventive actions

The strategy should connect all contamination-control measures rather than treating them as separate, unrelated procedures. WHO’s sterile-products GMP guideline places contamination-control strategy at the centre of sterile manufacturing.

Manufacturing Sections Required

The actual layout depends on the product and process, but a sterile facility may require the following areas.

General Areas

• Raw-material warehouse
• Packing-material warehouse
• Quarantine area
• Approved-material area
• Rejected-material area
• Sampling area
• Dispensing area
• Personnel change rooms
• Equipment washing area
• Component washing area
• Sterilisation area
• Production area
• Filling and sealing area
• Visual-inspection area
• Labelling and packing area
• Finished-goods quarantine
• Released finished-goods warehouse
• Returned and recalled-goods areas
• Quality-control laboratory
• Microbiology laboratory
• Stability section
• Utility area

Important Correction About Warehouses

A raw-material warehouse is not normally an aseptic area.

Materials are stored under controlled and documented conditions according to their status and storage requirements.

Only materials entering the sterile process are transferred through validated:

• Cleaning
• Disinfection
• Sterilisation
• Depyrogenation
• Airlock
• Pass-box procedures

Cleanroom Grades

Sterile production uses classified clean areas according to the risk of the operation.

Grade A

Grade A is the critical zone for high-risk operations such as:

• Aseptic filling
• Open sterile containers
• Aseptic connections
• Exposed sterile product
• Stopper bowls and filling needles
• Loading or unloading exposed sterile components

Grade A protection may be provided through:

• Unidirectional airflow
• Restricted Access Barrier System
• Isolator technology
• Appropriate HEPA filtration

Grade B

Grade B commonly provides the background environment for Grade A aseptic operations conducted in conventional cleanrooms.

Grade C and Grade D

These grades may be used for less critical preparation stages, depending on:

• Whether the product will be terminally sterilised
• Whether sterilising filtration will follow
• Product bioburden risk
• Process design
• The applicable approved manufacturing method

Cleanroom classification should be supported by qualification, risk assessment and the applicable GMP requirements.

HVAC System

A sterile facility requires a carefully designed HVAC system.

It may control:

• Air cleanliness
• Particle levels
• Microbial contamination
• Temperature
• Relative humidity
• Air changes
• Airflow direction
• Pressure differentials
• Recovery time

Separate air-handling systems may be needed for:

• Aseptic filling
• Component preparation
• Sterile change rooms
• Potent products
• Sensitising products
• Microbiology areas
• Non-sterile support areas

Air should not flow from a less clean area into a more critical area.

Airlocks and Pass Boxes

Airlocks help maintain separation between areas of different cleanliness.

Types may include:

• Personnel airlocks
• Material airlocks
• Equipment airlocks
• Pass boxes

Doors should be interlocked where necessary to prevent both doors from opening simultaneously.

Material transfer procedures should specify:

• Cleaning
• Disinfection
• Wrapping
• Sterilisation status
• Maximum holding time
• Transfer sequence

Personnel and Garments

People are one of the main contamination sources in aseptic production.

Only trained and qualified personnel should enter sterile areas.

Training should include:

• Microbiology
• Aseptic behaviour
• Gowning
• Cleanroom movement
• Intervention control
• Hygiene
• Disinfection
• Contamination risks
• Reporting of illness
• Documentation

Sterile-area clothing may include:

• Sterile coverall
• Hood
• Mask
• Goggles, where required
• Sterile gloves
• Sterile footwear

The complete gown should cover exposed skin and minimise release of particles and microorganisms.

Personnel should undergo periodic gowning qualification and microbiological monitoring.

Technical Staff Required

A parenteral manufacturing facility may require:

• Production head
• Manufacturing chemist
• Quality-control head
• Analytical chemist
• Microbiologist
• Quality-assurance manager
• Validation personnel
• Engineering personnel
• Production supervisors
• Trained sterile operators
• Visual inspectors
• Warehouse staff

Production and quality-control responsibilities should remain appropriately independent.

The Quality Unit should have authority to:

• Approve or reject materials
• Review batch records
• Approve or reject batches
• Investigate deviations
• Review sterility failures
• Manage complaints
• Initiate recalls
• Approve changes
• Review validation

Water for Parenteral Manufacturing

Water is a critical raw material in parenteral manufacturing.

Depending on the process, the facility may need:

• Potable water
• Purified water
• Water for Injection
• Clean steam

Water for Injection is commonly used for preparing aqueous parenteral products and for final rinsing of product-contact equipment where required.

The water system should be:

• Properly designed
• Qualified
• Sanitised
• Continuously circulated where applicable
• Chemically monitored
• Microbiologically monitored
• Protected against stagnation
• Maintained under change control

WHO maintains separate GMP guidance for pharmaceutical water systems in addition to sterile-product guidance.

Containers and Closures

Parenteral containers may include:

• Glass ampoules
• Tubular glass vials
• Moulded glass vials
• Plastic vials
• Prefilled syringes
• Cartridges
• Glass infusion bottles
• Plastic infusion bottles
• Flexible infusion bags

Closures may include:

• Rubber stoppers
• Elastomeric plungers
• Aluminium seals
• Flip-off caps
• Port closures

The container-closure system should be compatible with the formulation and provide protection throughout shelf life.

It should be evaluated for:

• Chemical compatibility
• Extractables and leachables
• Light protection
• Moisture protection
• Oxygen protection
• Breakage
• Closure integrity
• Sterilisation suitability
• Particulate generation

Manufacturing Process for Terminally Sterilised Liquid Parenterals

A typical process may include:

1. Receipt and quarantine of materials
2. Sampling and quality-control approval
3. Dispensing of ingredients
4. Preparation of Water for Injection
5. Preparation of bulk solution
6. Adjustment of pH or volume
7. Pre-filtration, where required
8. Bioburden sampling
9. Washing of containers
10. Sterilisation or depyrogenation of components
11. Filling
12. Stoppering or sealing
13. Terminal sterilisation
14. Leak or integrity testing
15. Visual inspection
16. Finished-product testing
17. Labelling and packing
18. Batch review and release

The time between bulk preparation, filling and sterilisation should be controlled and validated.

Manufacturing Process for Aseptically Filled Liquid Injections

A typical aseptic process may include:

1. Material receipt and approval
2. Dispensing
3. Bulk-solution preparation
4. Bioburden control
5. Pre-filtration
6. Sterilising-grade filtration
7. Filter-integrity testing
8. Transfer through a sterile closed system
9. Aseptic filling under Grade A protection
10. Stoppering or sealing
11. Capping
12. Container-closure integrity evaluation
13. Visual inspection
14. Sterility and endotoxin testing
15. Batch review and release

Sterilising-grade filters are commonly around 0.22 micrometre nominal pore size, but filter selection must be validated for the product, microorganism retention, compatibility and processing conditions.

Filtration should not remove the need for:

• Low starting bioburden
• Clean equipment
• Sterile components
• Controlled holding times
• Aseptic filling
• Filter-integrity testing
• Environmental control

Manufacturing Process for Dry-Powder Injections

Dry-powder injections may be prepared from a sterile active pharmaceutical ingredient or sterile formulation blend.

A typical process includes:

1. Receipt of sterile API or sterile bulk
2. Verification of sterility assurance and supplier controls
3. Receipt and preparation of containers and closures
4. Vial washing
5. Vial depyrogenation
6. Stopper washing and sterilisation
7. Transfer of sterile powder into the aseptic area
8. Aseptic powder filling
9. Stoppering
10. Crimp sealing
11. Weight verification
12. Container-closure integrity testing
13. Visual inspection
14. Labelling and packing
15. Finished-product testing
16. Batch release

Sterile powder cannot automatically be produced by autoclaving every raw material. Many APIs may be damaged by heat or moisture.

The sterilisation method must be scientifically suitable and validated.

Lyophilised Injection Manufacturing

Lyophilisation, or freeze-drying, is used for products that are unstable as liquids.

The typical process includes:

1. Bulk-solution preparation
2. Sterilising filtration
3. Aseptic filling
4. Partial stoppering
5. Transfer to lyophiliser
6. Freezing
7. Primary drying
8. Secondary drying
9. Stoppering inside the chamber
10. Removal from lyophiliser
11. Crimp sealing
12. Visual inspection
13. Container-closure integrity testing
14. Moisture testing
15. Reconstitution testing

The lyophilisation cycle should be validated for:

• Freezing rate
• Product temperature
• Shelf temperature
• Chamber pressure
• Primary-drying endpoint
• Secondary drying
• Residual moisture
• Product appearance
• Reconstitution time

Large-Volume Parenteral Manufacturing

LVP production usually requires highly automated systems because of:

• Large batch size
• High filling volume
• High particulate-risk exposure
• Large water requirement
• Large steriliser loads
• Container-integrity concerns

A typical LVP line may use:

• Glass bottles
• Polypropylene bottles
• Polyethylene containers
• Flexible bags
• Blow-Fill-Seal technology
• Form-Fill-Seal technology

Blow-Fill-Seal Technology

In Blow-Fill-Seal technology:

1. Plastic container is formed.
2. Product is filled.
3. Container is sealed.

These operations occur in one continuous automated cycle.

BFS can reduce manual interventions, but the process still requires:

• Machine qualification
• Environmental control
• Critical-zone protection
• Container-closure validation
• Sterilisation validation
• Media fills
• Maintenance controls

Form-Fill-Seal Technology

In Form-Fill-Seal systems, packaging film is formed into a container, filled and sealed in a continuous or highly integrated process.

It is commonly used for flexible infusion containers.

Sterilisation Methods

Moist-Heat Sterilisation

Steam sterilisation is commonly used for:

• Suitable finished products
• Rubber closures
• Equipment parts
• Garments
• Product-contact components
• Aqueous preparations

The cycle should be validated for:

• Time
• Temperature
• Pressure
• Heat penetration
• Load pattern
• Air removal
• Biological effectiveness
• Drying, where applicable

Dry-Heat Sterilisation and Depyrogenation

Dry heat may be used for:

• Glass containers
• Metal components
• Heat-stable materials
• Depyrogenation

The actual cycle should be validated according to:

• Equipment design
• Container type
• Line speed
• Temperature distribution
• Heat penetration
• Endotoxin reduction target

Sterilising Filtration

Sterilising filtration may be used for heat-sensitive solutions.

Validation should consider:

• Microbial retention
• Filter compatibility
• Adsorption
• Extractables
• Pressure
• Flow rate
• Filtration time
• Product temperature
• Maximum batch size
• Filter integrity

Gas and Radiation Sterilisation

Ethylene oxide, gamma radiation or electron-beam sterilisation may be suitable for certain components or devices.

Their use for pharmaceutical products requires scientific justification and validation because of:

• Residues
• Product degradation
• Packaging compatibility
• Dose distribution
• Material changes

Depyrogenation and Endotoxin Control

Sterility and absence of bacterial endotoxins are different quality requirements.

A sterile product can still contain endotoxins if contamination occurred before sterilisation.

Endotoxin control includes:

• High-quality water
• Low raw-material bioburden
• Clean equipment
• Short holding times
• Validated cleaning
• Depyrogenation of suitable components
• Microbial monitoring
• Endotoxin testing

Endotoxin cannot be reliably controlled only through final-product testing.

Machinery and Equipment

Component Preparation

• Ampoule washing machine
• Vial washing machine
• Rubber-stopper washing machine
• Ultrasonic washer
• Tunnel steriliser
• Dry-heat oven
• Autoclave
• Component preparation vessels

Solution Preparation

• Stainless-steel manufacturing vessel
• Pressure vessel
• Holding vessel
• Magnetic stirrer
• Homogeniser
• Transfer pump
• Load cells
• pH meter
• Temperature-control system
• Clean-in-place system
• Steam-in-place system

Filtration

• Pre-filter housing
• Sterilising-filter housing
• Membrane-filter assemblies
• Filter-integrity tester
• Sterile transfer lines

Filling and Sealing

• Ampoule filling and sealing machine
• Vial filling machine
• Powder filling machine
• Stoppering machine
• Crimping machine
• Prefilled-syringe filling line
• BFS machine
• FFS machine
• LVP bottle filling line
• Bag filling and sealing machine

Lyophilisation

• Pharmaceutical lyophiliser
• Refrigeration system
• Vacuum system
• Automatic loading and unloading, where applicable
• Chamber-cleaning system
• Stoppering arrangement

Inspection and Packing

• Visual-inspection machine
• Leak-testing machine
• High-voltage leak detector
• Vacuum leak tester
• Label application machine
• Cartoning machine
• Coding and serialization equipment

Quality-Control Tests

Depending on the product, finished-product testing may include:

• Description
• Identification
• Assay
• Related substances
• pH
• Osmolality or osmolarity
• Sterility
• Bacterial endotoxins
• Pyrogen testing, where applicable
• Visible particles
• Sub-visible particulate matter
• Extractable volume
• Fill volume
• Uniformity
• Preservative content
• Preservative effectiveness
• Reconstitution time
• Residual moisture
• Container-closure integrity
• Leak testing
• Potency
• Toxicity or biological tests, where applicable

The exact specification should follow the approved product dossier and applicable pharmacopoeial monograph.

Visual Inspection

Every parenteral container should undergo appropriate inspection for defects such as:

• Visible particles
• Fibres
• Glass fragments
• Black particles
• Improper fill volume
• Cracks
• Cosmetic defects
• Incomplete sealing
• Damaged stopper
• Incorrect crimping
• Discolouration
• Precipitation
• Container leakage

Manual inspectors should be trained and periodically qualified.

Automatic inspection machines should be qualified and challenged with representative defect sets.

Environmental Monitoring

A sterile facility should monitor:

• Non-viable particles
• Viable airborne microorganisms
• Settle plates
• Surface microorganisms
• Personnel gloves
• Personnel garments
• Temperature
• Relative humidity
• Pressure differentials
• Airflow

Monitoring locations and frequency should be based on risk and process knowledge.

Grade A areas require continuous or appropriately frequent monitoring during critical operations according to applicable GMP requirements.

Environmental-monitoring results should be:

• Reviewed promptly
• Trended
• Compared with alert and action limits
• Investigated when abnormal
• Included in batch review where relevant

Media Fill or Aseptic-Process Simulation

A media fill simulates the aseptic manufacturing process using a suitable microbiological growth medium.

It should represent:

• Normal production duration
• Maximum permitted interventions
• Routine interventions
• Worst-case line speed
• Shift changes
• Container sizes
• Holding times
• Operator involvement
• Lyophilisation steps, where applicable

Media fills are required initially and periodically for each aseptic process and qualified operator group according to the approved programme.

A failed media fill requires investigation and assessment of affected aseptic operations.

Filter-Integrity Testing

Sterilising filters should undergo integrity testing according to the validated process.

Tests may include:

• Bubble-point test
• Diffusion-flow test
• Pressure-hold test
• Water-intrusion test

Testing should demonstrate that the filter remained integral throughout processing.

Pre-use post-sterilisation integrity testing may be required or expected according to the applicable process and risk assessment, along with post-use testing.

Container-Closure Integrity

Container-closure integrity demonstrates that the sealed container protects the sterile product from contamination throughout shelf life.

Methods may include:

• Vacuum decay
• Pressure decay
• High-voltage leak detection
• Helium leak testing
• Dye ingress
• Microbial ingress
• Laser-based headspace analysis

The chosen method should be appropriate for:

• Container
• Closure
• Product
• Defect size
• Shelf-life requirement

Validation and Qualification

A parenteral facility requires extensive qualification and validation.

Qualification

• Design Qualification
• Installation Qualification
• Operational Qualification
• Performance Qualification

Validation

• Process validation
• Cleaning validation
• Sterilisation validation
• Depyrogenation validation
• Aseptic-process simulation
• Filter validation
• Holding-time validation
• HVAC qualification
• Water-system validation
• Container-closure integrity validation
• Computerised-system validation
• Transport validation
• Visual-inspection validation

Documentation Required

Records may include:

• Master Formula Record
• Batch Manufacturing Record
• Batch Packing Record
• Equipment logbook
• Cleaning records
• Sterilisation records
• Autoclave cycle records
• Tunnel-depyrogenation records
• Filter-integrity records
• Environmental-monitoring records
• Personnel-monitoring records
• Water-test records
• Differential-pressure records
• Temperature and humidity records
• Visual-inspection records
• Leak-test records
• Yield reconciliation
• Rejected-container records
• Label reconciliation
• Deviation reports
• CAPA records
• Change-control records
• Stability records
• Analytical reports
• Batch-release records

Important Batch Record Details

The batch record should normally identify:

• Product name
• Batch number
• Batch size
• Manufacturing dates
• Expiry date
• Raw-material quantities
• Control numbers
• Equipment used
• Mixing time
• Solution pH
• Filtration data
• Filling volume
• Environmental conditions
• Sterilisation cycle
• Number of containers filled
• Number rejected
• Actual yield
• Reconciliation
• Operators and supervisors
• Quality-control reports
• Quality-assurance release

Product Release

A batch should be released only after authorised Quality Assurance review.

Release review should include:

• Complete batch records
• Sterilisation records
• Environmental monitoring
• Filter-integrity results
• Finished-product testing
• Sterility results
• Bacterial-endotoxin results
• Deviations
• Yield reconciliation
• Packaging reconciliation
• Container-closure information

Sterility-test results alone are not sufficient to release a batch if the manufacturing process or environmental records show loss of control.

Common Manufacturing Mistakes

Avoid these mistakes:

• Treating final sterility testing as the main sterility assurance
• Assuming filtration alone makes a product sterile
• Using one fixed depyrogenation temperature for every container
• Keeping raw-material warehouses as poorly defined “aseptic” areas
• Ignoring personnel interventions
• Weak environmental monitoring
• No contamination-control strategy
• Inadequate media fills
• Poor water-system maintenance
• Missing filter-integrity tests
• Using unqualified visual inspectors
• Inadequate container-closure integrity testing
• Excessive bulk-solution holding time
• Poor endotoxin control
• Mixing sterile and non-sterile material flows
• Installing equipment before finalising product and process
• Copying another factory’s SOPs
• Releasing batches despite unexplained deviations

Investment Required

Parenteral manufacturing requires substantially higher investment than ordinary tablet, capsule or liquid manufacturing.

Major cost areas include:

• Industrial premises
• Sterile-facility construction
• Cleanroom panels
• HVAC
• Water for Injection system
• Clean-steam generator
• Autoclaves
• Depyrogenation tunnel
• Filling lines
• Lyophiliser, where required
• Quality-control laboratory
• Microbiology laboratory
• Stability chambers
• Environmental-monitoring instruments
• Validation
• Technical staff
• Backup utilities
• Product development
• Regulatory approvals
• Working capital

LVP, lyophilised, biological and aseptic prefilled-syringe facilities normally require much higher investment than a basic terminally sterilised SVP line.

Best Startup Strategy

A first-time manufacturer should not start every parenteral category together.

A practical strategy is:

1. Select one product category.
2. Decide whether it can be terminally sterilised.
3. Prepare a detailed feasibility report.
4. Engage sterile-manufacturing experts.
5. Finalise product and container systems.
6. Design the facility according to the process.
7. Obtain regulatory guidance before construction.
8. Install scalable equipment.
9. Establish quality systems early.
10. Conduct qualification and validation before commercial manufacture.

Whenever possible, a new company may first use a licensed third-party sterile manufacturer rather than immediately constructing its own parenteral plant.

Final Answer

Parenteral preparations are sterile medicines administered by injection, infusion or implantation.

They include:

• Small-Volume Parenterals
• Large-Volume Parenterals
• Liquid injections
• Dry-powder injections
• Lyophilised injections
• Prefilled syringes
• Infusion solutions

Their manufacture requires a much higher level of control than ordinary oral products.

The key requirements are:

• Properly designed sterile premises
• Qualified HVAC and water systems
• Trained personnel
• Validated sterilisation
• Validated aseptic processing
• Environmental monitoring
• Media-fill studies
• Endotoxin control
• Container-closure integrity
• Strong Quality Assurance review

Terminal sterilisation should be used whenever the product and container can tolerate it. Aseptic processing should be selected only when necessary and supported by a comprehensive contamination-control strategy.

In India, the facility should comply with the revised Schedule M, applicable product licences, pharmacopoeial requirements and State or Central Licensing Authority procedures.

Frequently Asked Questions

1. What are parenteral preparations?

Parenteral preparations are sterile medicines administered through injection, infusion or implantation.

2. What is an SVP?

An SVP is generally a Small-Volume Parenteral supplied in a container of 100 ml or less.

3. What is an LVP?

An LVP is generally a Large-Volume Parenteral supplied in a container containing more than 100 ml.

4. What is the difference between terminal sterilisation and aseptic filling?

Terminal sterilisation sterilises the sealed final container. Aseptic processing separately sterilises the product, components and equipment before filling under controlled conditions.

5. Which method is preferred?

Terminal sterilisation is preferred whenever scientifically and technically possible.

6. Is a 0.22-micron filter enough to ensure sterility?

No. Sterilising filtration must be validated and followed by protected aseptic filling, filter-integrity testing and environmental control.

7. Must vials always be depyrogenated above 300°C?

No. A validated time-and-temperature cycle should be established for the specific tunnel, vial and line speed.

8. Is Water for Injection required?

Water for Injection is generally required for aqueous parenteral preparations and applicable final rinsing operations.

9. What is a media fill?

A media fill is an aseptic-process simulation using a microbiological growth medium to evaluate the capability of the aseptic process.

10. What is container-closure integrity?

It is the ability of the sealed container to prevent entry of microorganisms and other contaminants throughout shelf life.

11. Are LVPs normally multi-dose?

No. Large-Volume Parenterals are generally single-dose preparations.

12. Can preservatives be used in LVPs?

LVPs normally do not contain antimicrobial preservatives unless specifically justified and permitted.

13. Is environmental monitoring compulsory?

Yes. Viable, non-viable, surface and personnel monitoring are fundamental controls in sterile manufacturing.

14. Can dry-powder APIs simply be autoclaved?

No. The sterilisation method must be compatible with the API. Many sterile powders are produced through specialised sterile processes or obtained from qualified sterile sources.

15. Which licence applies to LVP manufacturing in India?

The applicable route includes Forms 28D/28DA for LVP licensing under the relevant Central and State regulatory process. The current procedure should be confirmed through CDSCO and the concerned State Licensing Authority.

Looking for Ayurvedic Franchise or Distribution Opportunities?

Looking to start an Ayurvedic franchise, become a distributor, or launch your own herbal product range?

Elzac Herbal India offers:

• Ayurvedic & Herbal Product Range
• Franchise & Distribution Opportunities
• Third-Party Manufacturing
• Product Development Support
• Marketing Guidance
• PAN India Business Opportunities

Whether you are an entrepreneur, retailer, distributor, or healthcare professional, our team can help you explore the right business opportunity in the growing Ayurvedic sector.

Contact us today to discuss ayurvedic franchise, distribution, or third-party manufacturing opportunities.